莫匹罗星-白蛋白纳米粒治疗巨噬细胞内MRSA感染

Objective: Mupirocin-loaded albumin nanoparticles (Mup-BSA NPs) were successfully fabricated for treatment of intracellular MRSA infection in macrophages. Methods: Mup-BSA NPs were prepared by the desolvation method. The particle size and potential of nanoparticles were detected using a multi angle particle size and high sensitive zeta potential analyzer, and the morphology of nanoparticles were observed by transmission electron microscopy. The Fourier transform infrared spectroscopy(FT-IR) spectrometer was used to detect the characteristic absorption peaks of Mup-BSA NPs. Then, the drugloading efficiency and encapsulation efficiency of Mup-BSA NPs were quatified by high performance liquid chromatography. In addition, the intracellular bactericidal effect of Mup-BSA NPs was eavaluated in MRSA infected macrophage cells. Results: Mup-BSA NPs showed a spherical shape and well distribution (PDI = 0.139) with the average particle size of 131.42±1.03 nm. Their loading efficiency and encapsulation efficiency were 16.62% ±0.72% and 51.23%±0.95%, expectively. In MRSA-infected macrophages, Mup-BSA NPs exhibited significantly better inhibitory effects against intracellular bacteria compared to the free mupirocin. Conclusion: these results indicate that Mup-BSA NPs are potential candidates for targeted mupirocin delivery to macrophages. The albumin antibiotic delivery platform is a new strategy for the treatment of intracellular infection.